Activity Downloads

To Participate

To participate in this continuing education activity:

1. Review the activity description and objectives.
2. View the activity.
3. Complete the online post-test and activity evaluation.

A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)

 
 View more SIDPEC Activities ►
 

NOTE: If you attended the live CE activity titled "What Happened to HCAP? Approaches to Appropriate Therapy for Pneumonia Originating from the Community" that was held on October 3, 2017 at the SIDP Annual Meeting in San Diego, California, AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-17-416-L01-P), you are NOT eligible to also receive CE credit for this home-study activity.

Description

This program will look at the history of Healthcare associated pneumonia (HCAP) as well as the specific implications on use of broad spectrum antibiotics. Recent literature will be reviewed for issues such as multidrug resistance and the utility of HCAP in predicting such resistance. The current treatment guidelines and issues with them will be explored. The strategies for selection of appropriate therapy and the impact on broad spectrum antibiotic use will also be discussed.

This is a featured CE activity on the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) website. SIDPEC is the educational hub of the Society of Infectious Diseases Pharmacists (SIDP). The SIDPEC portal provides educational activities on infectious disease pharmacotherapy for clinical pharmacists, health‐systems pharmacists, community pharmacists, and other allied‐health disciplines.

Learning Objectives

The target audience for this activity is pharmacists. At the completion of this activity, the participant will be able to:

• Review the history of healthcare associated pneumonia (HCAP) as a definition and the implications on use of broad-spectrum antibiotics in the United States
• Discuss recent literature contradicting the utility of the HCAP definition as a predictor of multidrug resistant organisms in patients presenting to the hospital with pneumonia
• Outline alternative strategies to selection of empiric therapy in pneumonia based on pathogen-specific risk factors and the impact these may have on broad-spectrum antibiotic use

Faculty

Karl Madaras-Kelly, PharmD, MPH
Professor
College of Pharmacy
Idaho State University
Clinical Pharmacist
Boise Veterans Affairs Medical Center

Accreditation

Release Date: 10-3-2017
Expiration Date: 10-3-2019

Pharmacists

This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-17-416-H01-P has been assigned to this home-study knowledge-based activity (initial release date 10-3-2017). This activity is approved for 0.75 contact hours (0.075 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Dr. Madaras-Kelly has no relevant commercial or financial relationships to disclose.

Please note: The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.

Funding

This activity is partially supported by educational grants from Accelerate Diagnostics, Inc., CutisPharma, Inc., and Merck & Co., Inc.

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Download Handout